Setareh S Omran1, Michael P Lerario2, Gino Gialdini3, Alexander E Merkler1, Antonio Moya1, Monica L Chen3, Hooman Kamel1, Maria DeSancho4, Babak B Navi5. 1. Department of Neurology, Weill Cornell Medicine, New York, New York; Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York. 2. Department of Neurology, Weill Cornell Medicine, New York, New York; Department of Neurology, New York Presbyterian-Queens, New York, New York. 3. Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York. 4. Division of Hematology, Department of Medicine, Weill Cornell Medicine, New York, New York. 5. Department of Neurology, Weill Cornell Medicine, New York, New York; Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York. Electronic address: ban9003@med.cornell.edu.
Abstract
OBJECTIVE: We evaluated the ability of genetic and serological testing to diagnose clinically relevant thrombophilias in young adults with ischemic stroke. METHODS: We performed a retrospective cohort study of patients aged 18-65 years diagnosed with acute ischemic stroke at a comprehensive stroke center between 2011 and 2015 with laboratory testing for thrombophilia. The primary outcome was any positive thrombophilia screening test. The secondary outcome was a change in clinical management based on thrombophilia testing results. Logistic regression was used to assess whether the prespecified risk factors of age, sex, prior venous thromboembolism, family history of stroke, stroke subtype, and presence of patent foramen ovale were associated with outcomes. RESULTS: Among 196 young ischemic stroke patients, at least 1 positive thrombophilia test was identified in 85 patients (43%; 95% CI, 36%-51%) and 16 (8%; 95% CI, 5%-13%) had a resultant change in management. Among 111 patients with cryptogenic strokes, 49 (44%) had an abnormal thrombophilia test and 9 (8%) had a change in management. After excluding cases of isolated hyperhomocysteinemia or methylenetetrahydrofolate reductase or Factor V Leiden gene mutation heterozygosity, the proportion of patients with an abnormal thrombophilia screen decreased to 24%. Prespecified risk factors were not significantly associated with positive thrombophilia testing or a change in management. CONCLUSIONS: Two-of-five young patients with ischemic stroke who underwent thrombophilia screening at our institution had at least 1 positive test but only one-in-twelve had a resultant change in clinical management. Neither cryptogenic stroke subtype nor other studied clinical factors were associated with a prothrombotic state.
OBJECTIVE: We evaluated the ability of genetic and serological testing to diagnose clinically relevant thrombophilias in young adults with ischemic stroke. METHODS: We performed a retrospective cohort study of patients aged 18-65 years diagnosed with acute ischemic stroke at a comprehensive stroke center between 2011 and 2015 with laboratory testing for thrombophilia. The primary outcome was any positive thrombophilia screening test. The secondary outcome was a change in clinical management based on thrombophilia testing results. Logistic regression was used to assess whether the prespecified risk factors of age, sex, prior venous thromboembolism, family history of stroke, stroke subtype, and presence of patent foramen ovale were associated with outcomes. RESULTS: Among 196 young ischemic strokepatients, at least 1 positive thrombophilia test was identified in 85 patients (43%; 95% CI, 36%-51%) and 16 (8%; 95% CI, 5%-13%) had a resultant change in management. Among 111 patients with cryptogenic strokes, 49 (44%) had an abnormal thrombophilia test and 9 (8%) had a change in management. After excluding cases of isolated hyperhomocysteinemia or methylenetetrahydrofolate reductase or Factor V Leiden gene mutation heterozygosity, the proportion of patients with an abnormal thrombophilia screen decreased to 24%. Prespecified risk factors were not significantly associated with positive thrombophilia testing or a change in management. CONCLUSIONS: Two-of-five young patients with ischemic stroke who underwent thrombophilia screening at our institution had at least 1 positive test but only one-in-twelve had a resultant change in clinical management. Neither cryptogenic stroke subtype nor other studied clinical factors were associated with a prothrombotic state.
Authors: R Belvís; A Santamaría; J Martí-Fàbregas; D Cocho; M Borrell; J Fontcuberta; J L Martí-Vilalta Journal: Acta Neurol Scand Date: 2006-10 Impact factor: 3.209
Authors: S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis Journal: J Thromb Haemost Date: 2006-02 Impact factor: 5.824
Authors: Sanjay Sastry; Graham Riding; Julie Morris; David Taberner; Nicola Cherry; Anthony Heagerty; Charles McCollum Journal: J Am Coll Cardiol Date: 2006-07-25 Impact factor: 24.094
Authors: Steven R Levine; Robin L Brey; Barbara C Tilley; J L P Thompson; Ralph L Sacco; Robert R Sciacca; A Murphy; Yimeng Lu; Teresa M Costigan; Candi Rhine; Bruce Levin; Douglas A Triplett; J P Mohr Journal: JAMA Date: 2004-02-04 Impact factor: 56.272
Authors: Kristina Vrotniakaite-Bajerciene; Tobias Tritschler; Katarzyna Aleksandra Jalowiec; Helen Broughton; Justine Brodard; Naomi Azur Porret; Alan Haynes; Alicia Rovo; Johanna Anna Kremer Hovinga; Drahomir Aujesky; Anne Angelillo-Scherrer Journal: J Clin Med Date: 2022-07-19 Impact factor: 4.964
Authors: Francesco Janes; Roberta Giacomello; Francesca Blarasin; Martina Fabris; Simone Lorenzut; Gian Luigi Gigli; Francesco Curcio; Mariarosaria Valente Journal: Cureus Date: 2022-09-17
Authors: Thita Chiasakul; Elizabeth De Jesus; Jiayi Tong; Yong Chen; Mark Crowther; David Garcia; Chatree Chai-Adisaksopha; Steven R Messé; Adam Cuker Journal: J Am Heart Assoc Date: 2019-09-24 Impact factor: 5.501